Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | IGF1R | P08069 | 2/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5083969 | 0.92 | IGF1R (0.46) | CYP3A4IGF1RTNK2 | |
| SCHEMBL5086159 | 0.88 | TNK2 (0.35) | CYP3A4IGF1RTNK2SYKTGFBR1 | |
| SCHEMBL5082157 | 0.87 | IGF1R (0.38) | CYP3A4IGF1RTNK2 | |
| SCHEMBL5085497 | 0.85 | TNK2 (0.44) | CYP3A4IGF1RTNK2KDM4EALDH1A1 | |
| SCHEMBL5258044 | 0.83 | IGF1R (0.58) | CYP3A4IGF1RTNK2 | |
| SCHEMBL5085066 | 0.81 | IGF1R (0.44) | CYP3A4IGF1RTNK2TGFBR1 | |
| SCHEMBL5082928 | 0.79 | IGF1R (0.40) | CYP3A4IGF1RTNK2 | |
| SCHEMBL5083767 | 0.79 | IGF1R (0.46) | CYP3A4IGF1RTNK2KDM4EALDH1A1 | |
| SCHEMBL5139317 | 0.78 | IGF1R (0.51) | CYP3A4IGF1RTNK2 | |
| SCHEMBL5086104 | 0.77 | IGF1R (0.48) | CYP3A4IGF1RTNK2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979002-A2 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI Pharmaceuticals, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007075554-A2 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1740591-A1 | 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005097800-A1 | 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |